Medtronic's pivotal US CoreValve study proceeding as planned
This article was originally published in Clinica
Executive Summary
The trial of Medtronic's transcatheter aortic heart valve, CoreValve, is advancing, with the first patients having now received the device. The company hopes the study will secure US approval for the device.
You may also be interested in...
Normality Reasserts Itself For Biotech IPOs
The highs of the COVID-19 era, and the lows that supplanted it, are beginning to fade.
MRM Health Pulls A Pouchitis Hit Out Of The Bag
The mid-stage success is encouraging, but taking on Takeda won’t be easy.
Novartis Draws Out Its APPLAUSE
Another data drop from Fabhalta’s IgAN trial looks encouraging, despite a missing abstract.